AVZO-103 Clinical Trial
Phase 1/2
355
about 5 years
18+
9 sites in FL, MA, NC +4
About this study
Researchers are testing AVZO-103, a new drug, to see if it's safe and effective in people with urothelial cancer or other solid tumors. The trial will also look at how the body processes the drug and whether it can kill cancer cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AVZO-103
- 2.Take Combination Agent
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1), Objective Response Rate (ORR) (Phase 2)
Secondary: Disease Control Rate (DCR) (Phase 1 and 2), Duration of Response (DOR) (Phase 1 and 2), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 2), Objective Response Rate (ORR) (Phase 1), Overall Survival (OS) (Phase 1 and 2), PK Parameters: Accumulation ratio (AR) (Phase 1), PK Parameters: Apparent Clearance (CL/F) (Phase 1), PK Parameters: Apparent volume of distribution at steady-state (Vss) (Phase 1)
Oncology